<DOC>
	<DOCNO>NCT00401271</DOCNO>
	<brief_summary>The purpose trial evaluate safety , efficacy pharmacokinetics 100mg , 200mg , 300mg 400mg daily OPC-67683 , administer orally 14 consecutive day , patient uncomplicated , smear-positive pulmonary TB . The four OPC-67683 treatment group comprise 12 patient one standard therapy ( Rifafour e-275 ) group six patient . Trial 242-06-101 exploratory confirmatory trial hypothesis test statistically . The control group , six patient treat Rifafour , serve control confirm microbiological assessment trial .</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetics OPC-67683 Patients With Pulmonary Tuberculosis</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<criteria>Provide write , informed consent prior trialrelated procedure . Male female patient age 18 64 year , inclusive . Newly diagnose , previously untreated , uncomplicated , smear positive , pulmonary TB . A chest Xray find compatible TB . Sputum positive direct microscopy acidfast bacillus ( AFB ) ( least 1+ ) . Able produce adequate volume sputum ( 10mL estimate overnight production ) . Female patient childbearing potential must demonstrate negative pregnancy test result . Furthermore must agree use highly effective method contraception . Male patient must agree use adequate method contraception . Poor general condition delay treatment tolerate immediate hospital admission warrant . Rifampicinresistant bacteria detect sputum susceptibility test Screening . Treatment receive drug active M. tuberculosis within 3 month prior Screening . History allergy nitroimidazole derivates , rifamycin derivative , isoniazid derivative , pyrazinamide ethambutol . Clinical evidence severe extrathoracic TB ( miliary TB , abdominal TB , urogenital TB , osteoarthritic TB , TB meningitis ) . Evidence pulmonary silicosis , lung fibrosis , lung condition consider severe investigator ( TB ) . Presence chronic obstructive pulmonary disease asthma . Any clinically relevant concomitant condition renal impairment characterize serum creatinine level &gt; = 1.5xULN hepatic impairment alcohol abuse characterize ALT and/or aspartate transferase ( AST ) level 3xULN and/or gammaglutamyl transpeptidase ( GGT ) level 3xULN laboratory reference range . Known suspect alcohol drug abuse , , abuse sufficient enough compromise safety cooperation patient , opinion investigator , evident positive urine drug screen . Neuropathy , psychosis epilepsy . Clinically relevant change ECG atrioventricular ( AV ) block , prolongation QRS complex &gt; 120 millisecond ( male female patient ) , QTcB interval &gt; 430 millisecond male patient &gt; 450 millisecond female patient . Family history long QT syndrome and/or Torsade de Pointes . History current clinically relevant cardiovascular disorder hypokalaemia , heart failure , coronary heart disease , hypertension , arrhythmia symptom strongly suggestive problem ( example , syncope palpitation ) , tachyarrhythmia status myocardial infarction . Known bleed disorder family history bleeding disorder . Diabetes treat insulin . Evidence clinically significant metabolic , gastrointestinal , neurological , psychiatric endocrine disease , malignancy , abnormality ( indication study ) . Any disease condition use rifampicin , isoniazid , pyrazinamide ethambutol contraindicate . Any disease condition medicinal product list protocol , use . Treatment receive quinolones prednisolone within 3 month prior Screening . Administration IMP within 1 month prior Screening . Pregnancy , breastfeeding , plan conceive father child within timeframe describe informed consent form . Recent use methadone , benzodiazepine , cocaine , amphetamine/metamphetamine , tetrahydrocannabinol , barbiturate , tricyclic antidepressant , opiate determine urine drug screen . Helper/inducer T lymphocyte ( CD4 cell ) count &lt; =350x106/L . Use antiretroviral therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>